Literature DB >> 22374323

Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review.

H Chaussade1, F Bastides, S Lissandre, P Blouin, E Bailly, J Chandenier, E Gyan, L Bernard.   

Abstract

OBJECTIVES: Chronic disseminated candidiasis (CDC) is a disseminated fungal infection that is frequently seen in patients undergoing intensive treatment of haematological malignancies. The first signs of CDC appear during neutrophil recovery. Clinical and physiopathological characteristics of CDC suggest it belongs to the spectrum of fungus-related immune reconstitution inflammatory syndrome (IRIS). We report five cases of CDC treated with antifungal therapy and adjuvant corticosteroids to decrease the exacerbated inflammatory response.
METHODS: We conducted a retrospective study in the Haematology Department of the University Hospital of Tours, France. The five reported cases were treated for CDC with antifungal therapy and adjuvant corticosteroids.
RESULTS: Of the five cases of CDC, one was proven and four were possible, according to the 2008 European Organization for Research and Treatment of Cancer (EORTC) classification. All patients were being treated for acute leukaemia. In all cases, symptoms disappeared 2.8 days (range, 1-7) after the beginning of adjunctive corticosteroid therapy. Corticosteroids were administered on average for 146 days (range, 4 weeks-1 year) and antifungal therapy was administered for the duration of chemotherapy consolidation. There was no exacerbation of CDC symptoms during the next round of chemotherapy or bone marrow transplantation. One patient died from relapse of leukaemia.
CONCLUSIONS: Within the framework of IRIS, adjuvant corticosteroid therapy could rapidly improve CDC symptoms and allow continued chemotherapy without delay and without compromising the haematological prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374323     DOI: 10.1093/jac/dks044

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

2.  Chronic Disseminated Candidiasis Complicated by Immune Reconstitution Inflammatory Syndrome in Child with Acute Lymphoblastic Leukemia.

Authors:  Olga Zając-Spychała; Bogna Ukielska; Katarzyna Jończyk-Potoczna; Benigna Konatkowska; Jacek Wachowiak
Journal:  Case Rep Hematol       Date:  2016-10-09

3.  Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study.

Authors:  Inès Boussen; Quentin Lisan; Emmanuel Raffoux; Roberta Di Blasi; Nicolas Boissel; Eric Oksenhendler; Lionel Adès; Aliénor Xhaard; Stéphane Bretagne; Alexandre Alanio; Jean-Michel Molina; Blandine Denis
Journal:  Open Forum Infect Dis       Date:  2022-03-07       Impact factor: 3.835

4.  Use of antifungal drugs in hematology.

Authors:  Marcio Nucci
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 5.  Candida-Related Immune Response Inflammatory Syndrome Treated with Adjuvant Corticosteroids and Review of the Pediatric Literature.

Authors:  Dildar Bahar Genç; Sema Vural; Nafiye Urgancı; Tuğçe Kurtaraner; Nazan Dalgıç
Journal:  Turk J Haematol       Date:  2016-10-18       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.